321 related articles for article (PubMed ID: 22546857)
1. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
2. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.
Cozma D; Yu D; Hodawadekar S; Azvolinsky A; Grande S; Tobias JW; Metzgar MH; Paterson J; Erikson J; Marafioti T; Monroe JG; Atchison ML; Thomas-Tikhonenko A
J Clin Invest; 2007 Sep; 117(9):2602-10. PubMed ID: 17717600
[TBL] [Abstract][Full Text] [Related]
3. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
4. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.
Poe JC; Minard-Colin V; Kountikov EI; Haas KM; Tedder TF
J Immunol; 2012 Sep; 189(5):2318-25. PubMed ID: 22826319
[TBL] [Abstract][Full Text] [Related]
5. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
6. CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk.
Hobeika E; Levit-Zerdoun E; Anastasopoulou V; Pohlmeyer R; Altmeier S; Alsadeq A; Dobenecker MW; Pelanda R; Reth M
EMBO J; 2015 Apr; 34(7):925-39. PubMed ID: 25630702
[TBL] [Abstract][Full Text] [Related]
7. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
[TBL] [Abstract][Full Text] [Related]
8. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.
Varano G; Raffel S; Sormani M; Zanardi F; Lonardi S; Zasada C; Perucho L; Petrocelli V; Haake A; Lee AK; Bugatti M; Paul U; Van Anken E; Pasqualucci L; Rabadan R; Siebert R; Kempa S; Ponzoni M; Facchetti F; Rajewsky K; Casola S
Nature; 2017 Jun; 546(7657):302-306. PubMed ID: 28562582
[TBL] [Abstract][Full Text] [Related]
9. Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation.
Ishiura N; Nakashima H; Watanabe R; Kuwano Y; Adachi T; Takahashi Y; Tsubata T; Okochi H; Tamaki K; Tedder TF; Fujimoto M
Eur J Immunol; 2010 Apr; 40(4):1192-204. PubMed ID: 20101619
[TBL] [Abstract][Full Text] [Related]
10. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
11. Through an ITIM-independent mechanism the FcγRIIB blocks B cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19.
Xu L; Li G; Wang J; Fan Y; Wan Z; Zhang S; Shaheen S; Li J; Wang L; Yue C; Zhao Y; Wang F; Brzostowski J; Chen YH; Zheng W; Liu W
J Immunol; 2014 Jun; 192(11):5179-91. PubMed ID: 24790152
[TBL] [Abstract][Full Text] [Related]
12. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
13. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
14. Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.
He X; Kläsener K; Iype JM; Becker M; Maity PC; Cavallari M; Nielsen PJ; Yang J; Reth M
EMBO J; 2018 Jun; 37(11):. PubMed ID: 29669863
[TBL] [Abstract][Full Text] [Related]
15. The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3.
Christian SL; Sims PV; Gold MR
J Immunol; 2002 Jul; 169(2):758-69. PubMed ID: 12097378
[TBL] [Abstract][Full Text] [Related]
16. Cd19-dependent activation of Akt kinase in B-lymphocytes.
Otero DC; Omori SA; Rickert RC
J Biol Chem; 2001 Jan; 276(2):1474-8. PubMed ID: 11042164
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
18. Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements.
Högstrand K; Lindvall JM; Sundblad A; Grandien A
Eur J Immunol; 2019 Mar; 49(3):454-461. PubMed ID: 30664244
[TBL] [Abstract][Full Text] [Related]
19. Integration of activatory and inhibitory signals in human B-cells.
Sármay G; Koncz G; Gergely J
Immunol Lett; 1996 Dec; 54(2-3):93-100. PubMed ID: 9052860
[TBL] [Abstract][Full Text] [Related]
20. The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.
Wong DM; Li L; Jurado S; King A; Bamford R; Wall M; Walia MK; Kelly GL; Walkley CR; Tarlinton DM; Strasser A; Heierhorst J
Cell Rep; 2016 Feb; 14(6):1488-1499. PubMed ID: 26832406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
